Reference
Xu Z, et al. Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy. BMC Cancer 23: no pagination, No. 1, Dec 2023. Available from: URL: https://bmccancer.biomedcentral.com/
Rights and permissions
About this article
Cite this article
Afatinib/Furmonertinib. Reactions Weekly 1998, 21 (2024). https://doi.org/10.1007/s40278-024-53865-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-024-53865-8